Table 1.
Peripheral NLR/PLR and clinical characteristics of DLBCL patients.
| Characteristics | Total (n=182) | PLR | NLR | ||||
|---|---|---|---|---|---|---|---|
| ⩾150(n=90) | <150(n=92) | P-value | ⩾2.32(n=96) | <2.32(n=86) | P-value | ||
| Gender | 0.659 | 0.883 | |||||
| Male, n (%) | 96 | 49 | 47 | 50 | 46 | ||
| Age | 0.883 | 0.235 | |||||
| >60 | 90 | 44 | 46 | 43 | 47 | ||
| ⩽60 | 92 | 46 | 46 | 53 | 39 | ||
| Ann Arbor stage, n (%) | 0.431 | 0.001 | |||||
| I | 43 | 21 | 22 | 13 | 30 | ||
| II | 61 | 26 | 35 | 28 | 33 | ||
| III | 19 | 9 | 10 | 12 | 7 | ||
| IV | 59 | 34 | 25 | 43 | 16 | ||
| B symptoms, n (%) | 0.039 | 0.005 | |||||
| Yes | 35 | 23 | 12 | 26 | 9 | ||
| No | 147 | 67 | 80 | 70 | 77 | ||
| ECOG PS, n (%) | 0.032 | 0.048 | |||||
| <2 | 142 | 64 | 78 | 69 | 73 | ||
| ⩾2 | 40 | 26 | 14 | 27 | 13 | ||
| Extranodal sites of disease, n (%) | 0.285 | 0.002 | |||||
| >1 | 40 | 23 | 17 | 30 | 10 | ||
| ⩽1 | 142 | 67 | 75 | 66 | 76 | ||
| IPI, n (%) | 0.053 | 0.001 | |||||
| 0 | 37 | 16 | 21 | 16 | 21 | ||
| 1 | 55 | 20 | 35 | 18 | 37 | ||
| 2 | 38 | 21 | 17 | 24 | 14 | ||
| 3 | 30 | 18 | 12 | 23 | 7 | ||
| 4 | 14 | 11 | 3 | 10 | 4 | ||
| 5 | 8 | 4 | 4 | 5 | 3 | ||
| LDH, n (%) | 0.006 | 0.006 | |||||
| ⩽1 × ULN | 112 | 46 | 66 | 50 | 62 | ||
| >1 × ULN | 70 | 44 | 26 | 46 | 24 | ||
| Bone marrow involvement, n (%) | 0.567 | 1.000 | |||||
| YES | 13 | 5 | 8 | 7 | 6 | ||
| NO | 169 | 85 | 84 | 89 | 80 | ||
| Pathology type | 0.728 | 0.728 | |||||
| GCB subtype | 43 | 20 | 23 | 24 | 19 | ||
| Non-GCB subtype | 139 | 70 | 69 | 72 | 67 | ||
∗ Serum LDH level >ULN (upper limit of normal), the normal range of LDH in our center is 0-250U/L.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status; IPI, International Prognostic Index; LDH, lactate dehydrogenase; GCB, germinal center B cell.